India’s Ozone Targets Five Half-Price Generics For Indian Market
This article was originally published in PharmAsia News
Ozone Group says it plans to bring to India's market in July five drugs it will price at half the cost of what already is available. Ozone is one of a group of Indian pharmas seeking to counter an influx of questionable branded drugs into India by offering cheaper generics. Ozone's plans are focused on five drugs - an antibiotic and drugs to treat diarrhea, ulcers, pyretic and a painkiller. The firm's chairman and managing director. S.C. Sehgal, said the intent is to make available cheaper drugs with no sacrifice of quality, so he does not expect to garner major revenues from the drugs. (Click here for more
You may also be interested in...
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."